Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Videos

PlayAHA/ACC 2018 Cholesterol Guidelines also have good points

AHA/ACC 2018 Cholesterol Guidelines also have good points

Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital, London UK): A view of the AHA/ACC 2018 Cholesterol Guidelines The recent update to the AHA/ACC 2018 Cholesterol Guidelines has created much debate. Here, PCSK9 Forum Editor Professor Anthony Wierzbicki gives his view on one of the…

read more »
PlayCoronary artery calcium for stratifying risk in familial hypercholesterolaemia

Coronary artery calcium for stratifying risk in familial hypercholesterolaemia

Professor Raul Santos (Hospital Israelita Albert Einstein and University of São Paulo, Brazil): Is coronary artery calcium a tool for stratifying risk in familial hypercholesterolaemia? Professor Raul Santos discusses this pertinent question in the light of results from a recent cohort study in more than…

read more »
PlayPCSK9 Forum Inhibitors and Health Economics

PCSK9 Forum Inhibitors and Health Economics

The value of therapeutic intervention with a PCSK9 inhibitor is highly pertinent with increasingly finite resources for healthcare services. While PCSK9 inhibitors are undoubtedly extremely powerful LDL-lowering therapies that reduce cardiovascular events, their perceived cost has been a major barrier to uptake. The recent ODYSSEY…

read more »
PlayVIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a). Now the…

read more »
PlayHow best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes

How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes

Professor Gaetano De Ferrari (University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) discusses the importance of patient characteristics, and the timing and history of vascular disease.

read more »
PlayWhat’s in the PCSK9 pipeline?

What’s in the PCSK9 pipeline?

PCSK9 antibody therapy is indisputably effective, well tolerated and improves clinical outcomes; however, cost is an issue. PCSK9 Forum Editor Professor Derick Raal (University of Witwatersrand, Johnannesburg, South Africa) discusses what to look forward to after the PCSK9 monoclonal antibodies.

read more »